Skip to main content
Premium Trial:

Request an Annual Quote

Stanford, Rutgers, NIST Execute Licensing Deals; Technion, Weizmann Sell Royalty Rights

Licensing institution: Stanford University
Primary inventor: Undisclosed
Licensee: Telemolecular, Rancho Cordova, Calif.
Relevant patents: Undisclosed
Technology summary: Telomolecular has exclusively acquired from Stanford technology called Mitofusin I, which allows for the repair of damaged mitochondrial DNA. Telomolecular said it hopes to combine this tool with other of its products to reverse certain symptoms and signs of human aging.
Other details: Telemolecular must meet certain milestones in order to maintain permanent and exclusive worldwide licensing rights. Stanford is entitled to an undisclosed royalty on goods as well as certain undisclosed fees.

Licensing institution: Rutgers University
Primary inventor: Joachim Kohn
Licensee: Lux Bioscience, Jersey City, NJ
Relevant patents: Several undisclosed issued patents
Technology summary: Lux Bioscience has exclusively licensed IP from Rutgers related to polycarbonate, which Lux will use for ophthalmic applications. According to Lux, the technology represents a broader range of polymers that are bioerodable, based on monomeric building blocks, and demonstrate features making them useful for the controlled long-term delivery of medications to the eye.
Other details: The agreement builds upon a previous deal in which Lux licensed from Rutgers IP related to polyarylate. Lux said that the polycarbonate represents the next generation of this technology. Financial details were not disclosed.

Licensing institution: National Institute of Standards and Technology
Primary inventor: Michael Tarlov
Licensee: Stratos Biosystems, Seattle
Relevant patent: US No. 5,514,501
Technology summary: The patent protects a process for UV-photopatterning of thiolate monolayers self-assembled on gold, silver, and other substrates, which Stratos will use to produce surfaces or substrates for life sciences-related mass spectrometry. The license is exclusive.
Other details: Undisclosed

Licensing institution: Technion-Israel Institute of Technology and Weizmann Institute of Science
Primary inventors: Shoshana Merchav and Sha Meretzki
Licensee: Pluristem, New York City
Relevant patent: US No. 6,911,201
Technology summary: Pluristem has acquired patents related to PluriX, the company’s bioreactor technology that creates an environment similar to natural bone marrow and enhances the expression of mesenchymal stem cells that are obtained from the placenta, termed Placental eXpanded cells. Pluristem intends to use these cells in transplant therapies.
Other details: The purchased patents replace a previous license agreement with Technion and Weizmann in which Pluristem had exclusive rights to the technology in exchange for royalties. Pluristem said it now has the sole right to sub-license the technology without the obligation of paying 25 percent royalty fees to Technion and Weizmann.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.